Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAPK6_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAPK6_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAPK6_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MAPK6_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAPK6_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001635816 | Esophagus | ESCC | dendrite development | 130/8552 | 243/18723 | 8.33e-03 | 2.95e-02 | 130 |
GO:00163585 | Liver | NAFLD | dendrite development | 43/1882 | 243/18723 | 1.70e-04 | 3.07e-03 | 43 |
GO:00609963 | Liver | NAFLD | dendritic spine development | 21/1882 | 99/18723 | 7.26e-04 | 9.27e-03 | 21 |
GO:00609982 | Liver | NAFLD | regulation of dendritic spine development | 13/1882 | 61/18723 | 6.77e-03 | 4.79e-02 | 13 |
GO:0060999 | Liver | HCC | positive regulation of dendritic spine development | 27/7958 | 42/18723 | 3.60e-03 | 1.60e-02 | 27 |
GO:006099611 | Liver | HCC | dendritic spine development | 54/7958 | 99/18723 | 1.03e-02 | 3.86e-02 | 54 |
GO:001635811 | Liver | HCC | dendrite development | 121/7958 | 243/18723 | 1.26e-02 | 4.56e-02 | 121 |
GO:00609981 | Liver | HCC | regulation of dendritic spine development | 35/7958 | 61/18723 | 1.35e-02 | 4.82e-02 | 35 |
GO:001635810 | Oral cavity | OSCC | dendrite development | 113/7305 | 243/18723 | 1.00e-02 | 3.49e-02 | 113 |
GO:00609967 | Oral cavity | OSCC | dendritic spine development | 50/7305 | 99/18723 | 1.31e-02 | 4.34e-02 | 50 |
GO:001635815 | Oral cavity | EOLP | dendrite development | 55/2218 | 243/18723 | 1.43e-06 | 3.42e-05 | 55 |
GO:006099614 | Oral cavity | EOLP | dendritic spine development | 27/2218 | 99/18723 | 2.21e-05 | 3.37e-04 | 27 |
GO:00609986 | Oral cavity | EOLP | regulation of dendritic spine development | 18/2218 | 61/18723 | 1.69e-04 | 1.78e-03 | 18 |
GO:00609993 | Oral cavity | EOLP | positive regulation of dendritic spine development | 13/2218 | 42/18723 | 8.03e-04 | 6.31e-03 | 13 |
GO:001635822 | Oral cavity | NEOLP | dendrite development | 55/2005 | 243/18723 | 5.38e-08 | 2.16e-06 | 55 |
GO:006099621 | Oral cavity | NEOLP | dendritic spine development | 23/2005 | 99/18723 | 2.57e-04 | 2.62e-03 | 23 |
GO:006099813 | Oral cavity | NEOLP | regulation of dendritic spine development | 14/2005 | 61/18723 | 4.41e-03 | 2.48e-02 | 14 |
GO:00609968 | Skin | AK | dendritic spine development | 27/1910 | 99/18723 | 1.34e-06 | 4.15e-05 | 27 |
GO:001635817 | Skin | AK | dendrite development | 49/1910 | 243/18723 | 2.42e-06 | 6.72e-05 | 49 |
GO:00609987 | Skin | AK | regulation of dendritic spine development | 16/1910 | 61/18723 | 3.03e-04 | 3.12e-03 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAPK6 | SNV | Missense_Mutation | | c.147N>C | p.Lys49Asn | p.K49N | Q16659 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
MAPK6 | SNV | Missense_Mutation | | c.784N>C | p.Val262Leu | p.V262L | Q16659 | protein_coding | deleterious(0.05) | probably_damaging(0.956) | TCGA-BH-A202-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
MAPK6 | SNV | Missense_Mutation | novel | c.2158N>G | p.Leu720Val | p.L720V | Q16659 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.952) | TCGA-BH-A28O-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
MAPK6 | SNV | Missense_Mutation | | c.1159G>T | p.Asp387Tyr | p.D387Y | Q16659 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1XY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | tamoxiphen | SD |
MAPK6 | SNV | Missense_Mutation | novel | c.1460C>T | p.Ser487Phe | p.S487F | Q16659 | protein_coding | tolerated_low_confidence(0.24) | benign(0) | TCGA-DS-A5RQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
MAPK6 | SNV | Missense_Mutation | novel | c.2099C>G | p.Ser700Cys | p.S700C | Q16659 | protein_coding | tolerated_low_confidence(0.33) | benign(0.001) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
MAPK6 | SNV | Missense_Mutation | | c.140N>T | p.Ala47Val | p.A47V | Q16659 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAPK6 | SNV | Missense_Mutation | | c.7G>A | p.Glu3Lys | p.E3K | Q16659 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-A6-6648-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | PD |
MAPK6 | SNV | Missense_Mutation | novel | c.100G>T | p.Val34Phe | p.V34F | Q16659 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
MAPK6 | SNV | Missense_Mutation | | c.533T>C | p.Met178Thr | p.M178T | Q16659 | protein_coding | tolerated(0.3) | possibly_damaging(0.652) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |